Systemic Inflammation Characterizes Lack of Metabolic Health in Nonobese HIV-Infected Men

Ana N Monczor, Xiuhong Li, Frank J Palella Jr, Kristine M Erlandson, Dorothy Wiley, Lawrence A Kingsley, Wendy S Post, Lisa P Jacobson, Todd T Brown, Jordan E Lake, Ana N Monczor, Xiuhong Li, Frank J Palella Jr, Kristine M Erlandson, Dorothy Wiley, Lawrence A Kingsley, Wendy S Post, Lisa P Jacobson, Todd T Brown, Jordan E Lake

Abstract

Background: Increasing body mass index (BMI) is generally associated with loss of metabolic health, although some obese individuals remain metabolically healthy. Among nonobese men, HIV infection has been associated with a lower prevalence of metabolic health.

Methods: We conducted a cross-sectional analysis of 470 HIV-infected and 368 HIV-uninfected men enrolled in the Multicenter AIDS Cohort Study Cardiovascular substudy. Circulating biomarker levels were compared by BMI category and by HIV serostatus. Poisson regression with robust variance determined associations between metabolic health and circulating inflammatory biomarker levels after adjusting for factors previously associated with metabolic health.

Results: HIV-infected men were younger and less likely to be obese. Among HIV-infected, normal weight metabolically healthy men (compared to unhealthy) had significantly lower circulating levels of interleukin- (IL-) 6, soluble tumor necrosis factor receptors (sTNFR) I and II, and homeostatic model assessment of insulin resistance (HOMA-IR), higher adiponectin, less visceral fat, and more subcutaneous fat. Among HIV-uninfected normal weight men and obese men (regardless of HIV serostatus), metabolic health was associated only with higher levels of adiponectin, less visceral fat, and lower HOMA-IR values. In multivariate analyses restricted to HIV-infected men, lower hs-CRP, sTNFRI, sTNFRII, and HOMA-IR and higher adiponectin levels were associated with metabolic health. Additional adjustment for visceral adiposity did not alter results.

Conclusions: Among HIV-infected normal weight men, metabolic health was associated with less systemic inflammation, a relationship that, among normal weight men, was unique to HIV+ men and did not exist among obese men of either HIV serostatus.

References

    1. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. The New England Journal of Medicine. 2005;352(1):48–62. doi: 10.1056/NEJMra041811.
    1. Boccara F., Auclair M., Cohen A., et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antiviral Therapy. 2010;15(3):363–375. doi: 10.3851/IMP1533.
    1. Orlando G., Guaraldi G., Zona S., et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. Journal of Acquired Immune Deficiency Syndromes. 2012;59(5):494–497. doi: 10.1097/QAI.0b013e31824c8397.
    1. Alexopoulos N., Katritsis D., Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233(1):104–112. doi: 10.1016/j.atherosclerosis.2013.12.023.
    1. Lim S., Meigs J. B. Links between ectopic fat and vascular disease in humans. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(9):1820–1826. doi: 10.1161/ATVBAHA.114.303035.
    1. Lake J. E., Currier J. S. Metabolic disease in HIV infection. The Lancet Infectious Diseases. 2013;13(11):964–975. doi: 10.1016/S1473-3099(13)70271-8.
    1. Erlandson K. M., Lake J. E. Fat matters: understanding the role of adipose tissue in health in HIV infection. Current HIV/AIDS Reports. 2016;13(1):20–30. doi: 10.1007/s11904-016-0298-8.
    1. Kim D. J., Westfall A. O., Chamot E., et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. Journal of Acquired Immune Deficiency Syndromes. 2012;61(5):600–605. doi: 10.1097/QAI.0b013e31827303d5.
    1. Kroll A. F., Sprinz E., Leal S. C., Labrêa M. d. G., Setúbal S. Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil. Arquivos Brasileiros de Endocrinologia & Metabologia. 2012;56(2):137–141. doi: 10.1590/S0004-27302012000200007.
    1. Pasarica M., Gowronska-Kozak B., Burk D., et al. Adipose tissue collagen VI in obesity. The Journal of Clinical Endocrinology & Metabolism. 2009;94(12):5155–5162. doi: 10.1210/jc.2009-0947.
    1. Alligier M., Meugnier E., Debard C., et al. Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. The Journal of Clinical Endocrinology & Metabolism. 2012;97(2):E183–E192. doi: 10.1210/jc.2011-2314.
    1. Brestoff J. R., Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell. 2015;161(1):146–160. doi: 10.1016/j.cell.2015.02.022.
    1. Béréziat V., Cervera P., le Dour C., et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. The American Journal of Pathology. 2011;179(5):2443–2453. doi: 10.1016/j.ajpath.2011.07.049.
    1. Gallego-Escuredo J. M., Villarroya J., Domingo P., et al. Differentially altered molecular signature of visceral adipose tissue in HIV-1–associated lipodystrophy. Journal of Acquired Immune Deficiency Syndromes. 2013;64(2):142–148. doi: 10.1097/QAI.0b013e31829bdb67.
    1. Ketlogetswe K. S., Post W. S., Li X., et al. Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. AIDS. 2014;28(6):901–909. doi: 10.1097/QAD.0000000000000186.
    1. Grundy S. M., Brewer HB, Cleeman J. I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438. doi: 10.1161/01.CIR.0000111245.75752.C6.
    1. Lake J. E., Li X., Palella F. J., Jr., et al. Metabolic health across the BMI spectrum in HIV-infected and HIV-uninfected men. AIDS. 2018;32(1):49–57. doi: 10.1097/QAD.0000000000001651.
    1. Post W. S., Budoff M., Kingsley L., et al. Associations between HIV infection and subclinical coronary atherosclerosis. Annals of Internal Medicine. 2014;160(7):458–467. doi: 10.7326/M13-1754.
    1. Grundy S. M., Cleeman J. I., Daniels S. R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404.
    1. Potretzke A. M., Schmitz K. H., Jensen M. D. Preventing overestimation of pixels in computed tomography assessment of visceral fat. Obesity Research. 2004;12(10):1698–1701. doi: 10.1038/oby.2004.210.
    1. Deeks S. G., Tracy R., Douek D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633–645. doi: 10.1016/j.immuni.2013.10.001.
    1. Duprez D. A., Neuhaus J., Kuller L. H., et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9, article e44454) doi: 10.1371/journal.pone.0044454.
    1. McComsey G. A., Kitch D., Sax P. E., et al. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. Journal of Acquired Immune Deficiency Syndromes. 2014;65(2):167–174. doi: 10.1097/01.qai.0000437171.00504.41.
    1. Soderberg S., Ahren B., Jansson J. H., et al. Leptin is associated with increased risk of myocardial infarction. Journal of Internal Medicine. 1999;246(4):409–418. doi: 10.1046/j.1365-2796.1999.00571.x.
    1. Schulze M. B., Shai I., Rimm E. B., Li T., Rifai N., Hu F. B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54(2):534–539. doi: 10.2337/diabetes.54.2.534.
    1. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of Clinical Investigation. 2006;116(7):1784–1792. doi: 10.1172/JCI29126.
    1. Sinha U., Sinharay K., Sengupta N., Mukhopadhyay P. Benefits of leptin therapy in HIV patients. Indian Journal of Endocrinology and Metabolism. 2012;16(9):637–643. doi: 10.4103/2230-8210.105583.
    1. Veloso S., Escoté X., Ceperuelo-Mallafré V., et al. Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine. 2012;58(2):253–260. doi: 10.1016/j.cyto.2012.01.013.
    1. Carey D. G., Jenkins A. B., Campbell L. V., Freund J., Chisholm D. J. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45(5):633–638. doi: 10.2337/diab.45.5.633.
    1. Ofotokun I., Na L. H., Landovitz R. J., et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clinical Infectious Diseases. 2015;60(12):1842–1851. doi: 10.1093/cid/civ193.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner